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838FO-5 Immediate Postinfarction Shape Changes Predict the 
Outcome of the Remodeling Process 
Sina L. Moainie, T. Sloane Guy, IV, Joseph H. Gorman, III, Martin St. John-Sutton, Robed 
C. Gorman, University of Pennsylvania, Philadelphia, Pennsylvania. 
iNTRODUCTION: Post-infarction left ventricolar (LV) remodeling causes heart failure as 
a result of LV aneurysm (LVA) formation, ischemic mitral regurgitation (IMR) or ischemic 
cardiomyopathy (ICM), We hypothesized that early post-infarction changes in LV shape 
predict the ultimate outcome of the remodeling process, METHODS: Three groups of 5 
sheep underwent infarction (MI) of 23% of the left ventricle. Infarction in Group ~ led to 
LVA, in Group II it led to progressive IMR, and in Group III it led to ICM without IMR or 
LVA. All animals underwent echocardiography at baseline and 1 hr, 2, 5 and 8 weeks 
after MI to assess remodeling and LV shape changes. LV shape was assessed by the 
ratio of the LV internal diameter at end-systole to the left ventricular long axis length at 
end-systole (sphericity index). RESULTS: Group I (LVA) had immediate decline in ven- 
tricular sphericity after MI that persisted throughout he remodeling. Group II (IMR) had 
an increase in LV sphericity immediately that progressed over eight weeks. Group III 
(ICM) animals did not experience early changes in left ventdcular sphericity but had a 
progressive increase in sphericity over the eight-week study period. CONCLUSION: 
After MI, early changes in LV sphericity predict the final result of LV remodeling. An 
immediate increase in LV sphericity is correlated with the development of IMR while a 
delayed increase is seen with ICM. An early decrease is associated with LV aneurysm. 
Left Ventrlcular Sphericity Index 
"rimepoint Group I (LVA) Group II (IMR) Group III (ICM) 
Baseline 0.49(±0.04) 0.48(±0.03) 0.47(±0.08) 
1 Hour Post-Infarction 0.44(±0.06)* 0.52(±0.04) * 0.47(±0.09) 
2 Weeks Post-Infarction 0.44(±0.04) 0.54(±0.06) 0.48(±0.09) 
5 Weeks Post-Infarction 0,40(±0.08) 0,54(±0.06) 0.49(±0.09) 
8 Weeks Post-Infarction 0.41(±0.07) ^ 0.56(±0.08) ^ 0.54(±0.06) ^ 
*p<0.05 1 hour compared to baseline ^p<0.05 8 weeks compared to baseline 
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838FO-6 Endothelln Antagonism With Bosentan Improves 
Myocardial Mechanics and Ventricular Remodeling in 
Rats With Chronic Heart Failure 
~noeboro Schafhalter-Zooooth. John R. Teerlink, San Francisco VA Medical Center, San 
Francisco, California, UCSF, San Francisco, California. 
Background: The effect of ET antagonists on ventricular emodeling in CHF remains con- 
troversial and there has been limited investigation of the functional effects of ET blockade 
in CHF. We hypothesized that chronic therapy with bosentan would not only result in 
attenuation of progressive ventricular dilation, but would also result in functional improve- 
ments in myocardial mechanics. 
Methods: Adult male Sprague-Dawley rats (270-300g) underwent coronary artery ligation 
(CAL) and rats with ejection fraction <40% on conscious echocardiography at day 5-7 
after surgery were assigned to the CHF group. One week after surgery the animals were 
randomized to Placebo(P) or Bosentan (B;100 mg/kg/d) as a food additive. After 8 weeks 
of treatment, the animals underwent conscious echocardiography and in vivo hemody- 
namics and assessment of cardiac mechanics with a conductance catheter. The heads 
were excised and diastolic pressure-volume curves were obtained (n>9 in all groups). 
Results: Baseline data (EF, body weight) showed no differences between the treatment 
groups. There were no differences in body weight at 8 weeks, but echo EF was higher in 
the bosentan group (B, 26.4±2.3%, vs. P, 19.4±1.7%; p=0.028) and LVEDP was lower 
(B, 20.2±3.4 mmHg, vs. P, 29.5±2.5; p=0.05). Conductance catheter measurements 
demonstrated that bosentan treated rats had increased stroke volume (p=0.02), cardiac 
output (p=0.0:~), and increased maximal power (B, 93.5±17.5 mW, vs. P, 36.6±5.3; 
p=0.006; preload adjusted, p=0.01 ). Vena caval occlusions demonstrated a trend toward 
increased Ees (p=0.12) and ex vivo passive pressure-volume curves demonstrated 
marked reductions in ventricular volumes (LVEDVI @20mmHg: B, 2.17-~-0.17 ml/kg, vs. P, 
2.78±0.13; p=0.01) in the bosentan treated group, but no differences in stiffness con- 
stants over the 10-30 mmHg range. 
Conclusion: These data demonstrate that chronic ET blockade with bosentan results not 
only in significant attenuation of ventricular dilation, but also markedly improves ventricu- 
lar function. Whether this improvement ranslates into symptomatic benefit in patients is 
being studied in current clinical trials. 
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839-1 Vasopressin Receptor Blockade With Tolvaptan in 
Chronic Heart Failure: Differential Effects in 
Normonatremic and Hyponatremic Patients 
Mihai Gheorehiade, Marvin A. Konstam, James E. Udelson, John Ouyang, Cesare 
Odandi, Northwestern University School of Medicine, Chicago,///inois. 
Background: We have reported that chronic vasopressin V2 receptor blockade with 
tolvaptan (TLV) in pts with congestive heart failure (HF) reduces body weight and edema, 
and increases serum Na+. However, the effects of tolvaptan in HF patients with 
hyponafremia re not known. 
Methods: After a 3-day run-in period, 250 pts with HF and signs of congestion were ran- 
domized to placebo (n=62), TLV 30 mg (n=64), 45 mg (n=62) or 60 mg (n=62) qd for 25 
days. Pts were on standard therapy, not fluid restricted, and maintained on stable furo- 
semide (20-240 rng/day) throughout he study. 
Results: At baseline, hyponatremia (serum Na+ _<136 mEq/L) was seen in 34, 23, 23, and 
32 % of the placebo, TLV 30, 45, and 60 mg pts respectively. A significant and dose- 
dependent increase in urine volume was observed with TLV at day 1 in both nor- 
monatremic and hyponatremic pts. Changes in body weight (kg) and serum Na+ (mEqJL) 
at day 1 and 25 are shown in the table. No changes in serum K+ or other laboratory val. 
ues, and BP were observed. In patients with HF and signs of congestion, TLV therapy 
reduced body weight and edema to a similar degree irrespective of serum sodium at 
baseline. Although serum Na+ increased at day 1 in both groups, if returned to baseline 
by day 25 in normonatremic pts, while remained normalized in hyponatremic pts. 
Conclusions: In addition to reducing body weight and lessening edema, "{'LV therapy nor- 
malizes serum sodium in pts with HF and hyponatremia. 
Day PLC TLV 30mg TLV 45mg TLV 60mg 
Body Weight Hypo 1 +0.3±1.0 -0.2±0.7 -1.2±1.5" -0.5±1.2" 
25 +0.4±1.8 -0.4±1,7 -1.3±3.3* -0.7±1.5 
Normo 1 +0.3±1.7 -1.0±1.0" -0.9±2.0" -0.9±0.9* 
25 +0.7±2.2 -1.0±2.3* -1.0±2.1 -0.4±2.0* 
Serum Sodium Hypo 1 +1.2±1.6 +3,6±2.1" +3.3±2.4* +5.2±2.1" 
25 +1.0±2,8 +2.1±4,2 +1.5±2.3 +4.3±2.4* 
Normo 1 -1.8±7.4 +2.3±2.4* +2.9±2.4* +2.6±2.5* 
25 -0.6±2.8 +0.2±2.5 -0,5±3.0 -0.4±2.6 
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839*2 Cardiac Resynchronization Therapy Reduces Morbidity 
in Patients With Moderate to Severe Systolic Heart 
Failure and Intraventricular Conduction Delays 
William T. Abraham. Westby Fisher, Andrew Smith, David DeLurgio, Evan Loh, Angel 
Leon, Dusan Kocovic, Alfredo Clavell, David Hayes, University of Kentucky, Lexington, 
Kentucky, Crawford Long./Emoty University Hospital, University of Pennsylvania, Mayo 
Clinic. 
Background: Cardiac resynchronization therapy (CRT) has been demonstrated to 
improve exercise capacity, quality of life and cardiac function in moderate to severe heart 
failure patients with systolic dysfunction and a wide QRS. The impact of CRT on survival 
and hospitalization for heart failure has not been determined. Methods: The Multicenter 
InSync Clinical Evaluation included secondary objectives to assess survival and hospital- 
ization. Inclusion criteria were: NYHA Class III or IV HI=, LVEF 3 35%, LVEDD 3 55 mm, 
stable and optimal medical regimen, and a QRS duration 3130 msec, without pacing indi- 
cations. All patients were implanted with a CRT system. Patients were randomly 
assigned to either CRT or no CR (Contro}) for 6 months. Using a time to event analysis 
our objective for this substudy was to assess the impact of CRT on survival and hospital- 
ization in a 6 month period. Results: A total of 225 patients were assigned to the Control 
group, and 228 were assigned to CRT. Freedom from an event (95% CI) at 6 months for 
Control is 81.0% (75.1%, 85.6%), and for CRT is 87.3% (82.0%, 91.1%) with a relative 
risk of 0.615 (0.382, 0.990), P=0.043. Conclusion: CRT improves the freedom from major 
morbid events for select heart failure patients. 
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839-3 Efficacy and Safety of Carvedilol In Patients With 
Severe Chronic Heart Failure and Low Systolic Blood 
Pressure: Results of the COPERNICUS Study 
Jean L. Rouleau. Michael B, Fowler, Henry Krum, Hugo A. Katus, Andrew J. Coats, 
Michal Tenders, Paul Mohacsi, Ildika Amann-Zalan, Terry L Holcslaw, Ellen B. Roecker, 
Milton Packer, for the COPERNICUS Study Group, Mt. Sinai Hospital, Toronto, Canada. 
Background. Since survival trials with metoprolol and bisoprolol excluded patients with a 
systolic blood pressure (SBP) < 100mm Hg, many physicians are reluctant to use ~- 
blockers in such patients, especially those with a vasodilatory effect. 
Methods. We evaluated the effects of carvedilol (CRV) vs placebo (PBO) in 2289 patients 
